Skip to main content
. 2010 Oct 18;120(11):3979–3995. doi: 10.1172/JCI42315

Figure 10. Pharmacological blockade of S1PR2 inhibits atherosclerosis.

Figure 10

(A) S1PR2 antagonist JTE-K1 (25 mg/kg) was dosed to S1pr2+/+Apoe–/– mice by oral gavage starting 2 weeks before 8 weeks of HCD. Representative oil red O staining of spread aortas from mice given vehicle (n = 7) or JTE-K1 (n = 5). (B) Quantified data of oil red O–stained plaque areas are shown. *P < 0.05. (C and D) Immunostaining of Mac-3 (C) and α-SMA (D) in the sections of the aortas from S1pr2+/+Apoe–/– mice given vehicle or JTE-K1. Scale bars: 50 μm. Quantified data are shown in the lower panels (n = 5 each). *P < 0.05. (E) Uptake of Dil-labeled ac-LDL in JTE-K1 treated and nontreated S1pr2+/+Apoe–/– macrophages. Quantified data are shown (lower) (n = 3 each). Scale bars: 20 μm. *P < 0.05. (F) Cholesterol efflux in JTE-K1–treated and nontreated S1pr2+/+Apoe–/– macrophages (n = 3 each). *P < 0.05. Data are expressed as mean ± SEM.